Which SSRI is safest for patients with CVD and major depressive disorder?

JAAPA. 2021 Apr 1;34(4):18-19. doi: 10.1097/01.JAA.0000735792.92508.a6.

Abstract

Major depressive disorder is a common mood disorder and presents increased morbidity and mortality risks for patients with comorbid cardiovascular disease (CVD). Selective serotonin reuptake inhibitors (SSRIs) are a cornerstone of treatment for major depressive disorder, given their relative safety and affordability compared with other antidepressant classes, and SSRIs frequently are used in patients with CVD. However, clinicians should carefully weigh safety considerations before prescribing SSRIs in these patients. This article reviews the safety of SSRIs in patients with CVD and discusses SSRI selection.

Publication types

  • Review

MeSH terms

  • Antidepressive Agents / adverse effects
  • Cardiovascular Diseases* / drug therapy
  • Depressive Disorder, Major* / drug therapy
  • Humans
  • Selective Serotonin Reuptake Inhibitors / adverse effects

Substances

  • Antidepressive Agents
  • Serotonin Uptake Inhibitors